IPH-6501

Innate Pharma's IPH6501, a tetraspecific NK cell engager targeting CD20 B cells for Non-Hodgkin Lymphoma, will be featured at the European Hematology Association Congress in June 2025.

Innate Pharma has initiated a Phase 1 clinical trial (NCT06781983) to evaluate the safety and tolerability of IPH4502 in patients with advanced solid tumors expressing Nectin-4.

Innate Pharma SA has announced a comprehensive strategy aimed at driving sustainable growth and innovation in pharmaceutical R&D. Key highlights include the presentation of lacutamab's quality-of-life improvements in CTCL patients, a significant investment for IPH6501 development in follicular lymphoma, and FDA clearance for a new ADC targeting solid tumors.

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) have entered into an agreement to clinically study IPH6501 in follicular lymphoma.

Innate Pharma's IPH6501, a tetra-specific NK cell engager, targets CD20 and activates NK cells via NKp46, CD16, and an IL-2 variant receptor, showing potential in B-NHL.